{
    "nctId": "NCT06355024",
    "briefTitle": "Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer",
    "officialTitle": "a Pilot Study to Explore the Efficacy of Inosine Reversing Chemo Resistance in Triple Negative Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n- ECOG Performance Status of 0, 1\n\n* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)\n* Radiologic/objective evidence of recurrence or disease progression after chemotherapy for metastatic breast cancer (MBC)\n* Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)\n* have the cognitive ability to understand the protocol and be willing to participate and to be followed up\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing CNS metastases\n* Active or history of autoimmune disease or immune deficiency\n* Significant cardiovascular disease\n* History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death\n* Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* History of allergies to the drug components of this trial\n* Patients who have been using oral steroid hormones for a long time will need to stop for 4 weeks if they have used them occasionally in the past",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}